Schisandrin A in Schisandra chinensis Upregulates the LDL Receptor by Inhibiting PCSK9 Protein Stabilization in Steatotic Model
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Schisandra chinensis extract (SCE) protects against hypocholesterolemia by inhibiting proprotein convertase subtilisin/kexin 9 (PCSK9) protein stabilization. We hypothesized that the hypocholesterolemic activity of SCE can be attributable to upregulation of the PCSK9 inhibition-associated low-density lipoprotein receptor (LDLR). Male mice were fed a low-fat diet or a Western diet (WD) containing SCE at 1% for 12 weeks. WD increased final body weight and blood LDL cholesterol levels as well as alanine transaminase and aspartate aminotransferase expression. However, SCE supplementation significantly attenuated the increase in blood markers caused by WD. SCE also attenuated WDmediated increases in hepatic LDLR protein expression in the obese mice. In addition, SCE increased LDLR protein expression and attenuated cellular PCSK9 levels in HepG2 cells supplemented with delipidated serum (DLPS). Non-toxic concentrations of schisandrin A (SA), one of the active components of SCE, significantly increased LDLR expression and tended to decrease PCSK9 protein levels in DLPS-treated HepG2 cells. High levels of SA-mediated PCSK9 attenuation was not attributable to reduced PCSK9 gene expression, but was associated with free PCSK9 protein degradation in this cell model. Our findings show that PCSK9 secretion can be significantly reduced by SA treatment, contributing to reductions in free cholesterol levels.
Abstract
Schisandra chinensis extract (SCE) protects against hypocholesterolemia by inhibiting proprotein convertase subtilisin/kexin 9 (PCSK9) protein stabilization. We hypothesized that the hypocholesterolemic activity of SCE can be attributable to upregulation of the PCSK9 inhibition-associated low-density lipoprotein receptor (LDLR). Male mice were fed a low-fat diet or a Western diet (WD) containing SCE at 1% for 12 weeks. WD increased final body weight and blood LDL cholesterol levels as well as alanine transaminase and aspartate aminotransferase expression. However, SCE supplementation significantly attenuated the increase in blood markers caused by WD. SCE also attenuated WDmediated increases in hepatic LDLR protein expression in the obese mice. In addition, SCE increased LDLR protein expression and attenuated cellular PCSK9 levels in HepG2 cells supplemented with delipidated serum (DLPS). Non-toxic concentrations of schisandrin A (SA), one of the active components of SCE, significantly increased LDLR expression and tended to decrease PCSK9 protein levels in DLPS-treated HepG2 cells. High levels of SA-mediated PCSK9 attenuation was not attributable to reduced PCSK9 gene expression, but was associated with free PCSK9 protein degradation in this cell model. Our findings show that PCSK9 secretion can be significantly reduced by SA treatment, contributing to reductions in free cholesterol levels.
참고문헌 (52)
- Joseph P, "Reducing the global burden of cardiovascular disease, part 1 : the epidemiology and risk factors", Circ. Res, 121, pp.677~694 (2017)
- Roth GA, "Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015", J. Am. Coll. Cardiol, 70, pp.1~25 (2017)
- Herrington W, "Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease", Circ. Res, 118, pp.535~546 (2016)
- Baigent C, "Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170, 000 participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
- Lewington S, "Blood cholesterol and vascular mortality by age, sex, and blood pressure : a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths", Lancet, 370, pp.1829~1839 (2007)
- Di Angelantonio E, "Major lipids, apolipoproteins, and risk of vascular disease", JAMA, 302, pp.1993~2000 (2009)
- Hegsted DM, "Dietary fat and serum lipids : an evaluation of the experimental data", Am. J. Clin. Nutr, 57, pp.875~883 (1993)
- Keys A, "Prediction of serum-cholesterol responses of man to changes in fats in the diet", Lancet, 273, pp.959~966 (1957)
- Clarke R, "Dietary lipids and blood cholesterol : quantitative meta-analysis of metabolic ward studies", BMJ, 314, pp.112~117 (1997)
- Dattilo AM, "Effects of weight reduction on blood lipids and lipoproteins : a meta-analysis", Am. J. Clin. Nutr, 56, pp.320~328 (1992)
- Patriki D, "PCSK 9 : a link between inflammation and atherosclerosis", Curr. Med. Chem, 29, pp.251~267 (2021)
- Leander K, "Circulating proprotein convertase subtilisin", kexin type 9(PCSK9)predicts future risk of cardiovascular events independently of established risk factors, 2016, pp.133, 1230~1239
- Ruscica M, "Circulating levels of proprotein convertase subtilisin", kexin type 9 and arterial stiffness in a large population sample : data from the brisighella heart study, 2017, pp.6, e005764~
- Horton JD, "Molecular biology of PCSK9 : Its role in LDL metabolism", Trends Biochem. Sci, 32, pp.71~77 (2007)
- Xu S, "Small molecules as inhibitors of PCSK9 : current status and future challenges", Eur. J. Med. Chem, 162, pp.212~233 (2019)
- Szopa A, "Current knowledge of Schisandra chinensis (Turcz.) Baill.(Chinese magnolia vine) as a medicinal plant species: a review on the bioactive components, pharmacological properties, analytical and biotechnological studies", Phytochem. Rev, 16, pp.195~218 (2017)
- Kopustinskiene DM, "Antioxidant effects of Schisandra chinensis fruits and their active constituents", Antioxidants, 10, pp.620~ (2021)
- Seo HJ, "Analysis of dibenzocyclooctadiene lignans in Omija Wine and Cheong by liquid chromatography-tandem mass spectrometry", Mass. Spectrom. Lett, 11, pp.30~35 (2020)
- Jeong HJ, "Sterol-dependent regulation of proprotein convertase subtilisin", kexin type 9 expression by sterol-regulatory element binding protein-2, 2008, pp.49, 399~409
- Hwang JT, "The cholesterol-lowering effect of Capsella Bursa-Pastoris is mediated via SREBP2 and HNF-1alpha-regulated PCSK9 inhibition in obese mice and HepG2 cells", Foods, 10, pp.408~ (2021)
- Morrison MC, "Obeticholic acid modulates serum metabolites and gene signatures characteristic of human NASH and attenuates inflammation and fibrosis progression in Ldlr-", -.leiden mice, 2018, pp.2, 1513~1532
- Tengeler AC, "Propionic acid and not caproic acid, attenuates nonalcoholic steatohepatitis and improves(cerebro)vascular functions in obese Ldlr(-", -), 2020, pp.34, 9575~9593
- Li H, "Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine", J. Biol. Chem, 284, pp.28885~28895 (2009)
- Lambert G, "The PCSK9 decade", J. Lipid. Res, 53, pp.2515~2524 (2012)
- Maxfield FR, "Role of cholesterol and lipid organization in disease", Nature, 438, pp.612~621 (2005)
- Estronca LM, "Homeostasis of free cholesterol in the blood : a preliminary evaluation and modeling of its passive transport", J. Lipid. Res, 55, pp.1033~1043 (2014)
- Rothblat GH, "High-density lipoprotein heterogeneity and function in reverse cholesterol transport", Curr. Opin. Lipidol, 21, pp.229~238 (2010)
- Xu X, "Simvastatin promotes NPC1-mediated free cholesterol efflux from lysosomes through CYP7A1", LXRalpha signalling pathway in oxLDL-loaded macrophages, 2017, pp.21, 364~374
- Pfisterer SG, "LDL-cholesterol transport to the endoplasmic reticulum : current concepts", Curr. Opin. Lipidol, 27, pp.282~287 (2016)
- Vanier MT, "Complex lipid trafficking in Niemann-Pick disease type C", J. Inherit. Metab. Dis, 38, pp.187~199 (2015)
- Tall AR, "Cholesterol, inflammation and innate immunity", Nat. Rev. Immunol, 15, pp.104~116 (2015)
- Zheng XX, "Green tea intake lowers fasting serum total and LDL cholesterol in adults : a meta-analysis of 14 randomized controlled trials", Am. J. Clin. Nutr, 94, pp.601~610 (2011)
- Park JY, "The mechanism of vasorelaxation induced by Schisandra chinensis extract in rat thoracic aorta", J. Ethnopharmacol, 121, pp.69~73 (2009)
- Brown MS, "How LDL receptors influence cholesterol and atherosclerosis", Sci. Am, 251, pp.58~66 (1984)
- Sirinian MI, "Adaptor protein ARH is recruited to the plasma membrane by low density lipoprotein(LDL)binding and modulates endocytosis of the LDL", LDL receptor complex in hepatocytes, 2005, pp.280, 38416~38423
- Ragusa R, "PCSK9 and atherosclerosis : looking beyond LDL regulation", Eur. J. Clin. Invest, 51, pp.e13459~ (2021)
- Macchi C, "A new dawn for managing dyslipidemias : the era of RNA-based therapies", Pharmacol. Res, 150, pp.104413~ (2019)
- Choi HK, "Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells", Food Funct, 8, pp.4582~4591 (2017)
- Choi HK, "Allium tuberosum reverses PCSK9-mediated LDLR degradation by inhibition of HNF1α", J. Korean Soc. Food Sci. Nutr, 46, pp.1278~1285 (2017)
- Wang F, "Naringin alleviates atherosclerosis in ApoE(-", -)mice by regulating cholesterol metabolism involved in gut microbiota remodeling, 2020, pp.68, 12651~12660
- Hwang JT, "Butein synergizes with statin to upregulate low-density lipoprotein receptor through HNF1alpha-mediated PCSK9 inhibition in HepG2 cells", J. Med. Food, 23, pp.1102~1108 (2020)
- Cui CJ, "Beneficial impact of epigallocatechingallate on LDL-C through PCSK9", LDLR pathway by blocking HNF1alpha and activating FoxO3a, 2020, pp.18, 1~13
- Jia Q, "Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARgamma, LXRalpha and ABCA1", Int. J. Mol. Med, 44, pp.893~902 (2019)
- Dong Z, "Silibinin A decreases statininduced PCSK9 expression in human hepatoblastoma HepG2cells", Mol. Med. Rep, 20, pp.1383~1392 (2019)
- Gao WY, "Pinostrobin inhibits proprotein convertase subtilisin", kexin-type 9(PCSK9)gene expression through the modulation of FoxO3a protein in HepG2 cells, 2018, pp.66, 6083~6093
- Razgonova M, "Rapid mass spectrometric study of a supercritical CO2-extract from woody liana Schisandra chinensis by HPLC-SPD-ESI-MS", MS, 2020, pp.25, 2689~
- Kim Y, "Isolation and quantitative analysis of schisandrin, gomisin A and gomisin M2 from Schisandra chinensis", Korean J. Pharmacogn, 50, pp.148~153 (2019)
- Choi YH, "Schisandrin A prevents oxidative stress-induced DNA damage and apoptosis by attenuating ROS generation in C2C12 cells", Biomed. Pharmacother, 106, pp.902~909 (2018)
- Fu K, "A review : pharmacology and pharmacokinetics of schisandrin A", Phytother. Res, 36, pp.2375~2393 (2022)
- Kwon DH, "Schisandrin A suppresses lipopolysaccharide-induced inflammation and oxidative stress in RAW 264.7 macrophages by suppressing the NF-κB, MAPKs and PI3K", Akt pathways and activating Nrf2, Int. J. Mol. Med, pp.2018, 41[DOI]
- Jeong MJ, "Schizandrin A supplementation improves nonalcoholic fatty liver disease in mice fed a high-fat and high-cholesterol diet", Nutr. Res, 64, pp.64~71 (2019)
- Sun JH, "Metabolomics study of the therapeutic mechanism of Schisandra chinensis lignans in diet-induced hyperlipidemia mice", Lipids Health Dis, 16, pp.145~ (2017)